Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 2/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.49 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL67237 | 0.94 | LMNA (0.59) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL29757088 | 0.94 | LMNA (0.59) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL65737 | 0.94 | LMNA (0.59) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL20769804 | 0.94 | LMNA (0.59) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL1715 | 0.94 | LMNA (0.59) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL16820451 | 0.92 | LMNA (0.58) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL5598361 | 0.92 | LMNA (0.58) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL2008283 | 0.92 | LMNA (0.58) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| Methane SCHEMBL7338694 | 0.92 | LMNA (0.58) | LMNAHSD17B10CYP2C19ALDH1A1POLB | |
| SCHEMBL9171150 | 0.92 | LMNA (0.58) | LMNAHSD17B10CYP2C19ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11357748-B2 | Methods for treating mendelian disorders of the epigenetic machinery | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-06-14 | — | — | US | disclosed |
| US-10568854-B2 | Compositions and methods for treating kabuki syndrome and related disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170100354-A1 | COMPOSITIONS AND METHODS FOR TREATING KABUKI SYNDROME AND RELATED DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-04-13 | — | — | US | disclosed |
| US-20170095436-A1 | METHODS FOR TREATING MENDELIAN DISORDERS OF THE EPIGENETIC MACHINERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-04-06 | — | — | US | disclosed |
| WO-2015184279-A1 | COMPOSITIONS AND METHODS FOR TREATING KABUKI SYNDROME AND RELATED DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015184260-A2 | METHODS FOR TREATING MENDELIAN DISORDERS OF THE EPIGENETIC MACHINERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-12-03 | — | — | WO | disclosed |
| US-20120108522-A1 | HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER | UNIVERSITY OF MARYLAND, BALTIMORE | 2012-05-03 | — | — | US | disclosed |
| US-8110550-B2 | HDAC inhibitors and hormone targeted drugs for the treatment of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2012-02-07 | — | — | US | disclosed |
| EP-2359828-A1 | HDAC inhibitors and hormone targeted drugs for the treatment of cancer | University of Maryland, Baltimore (US) | 2011-08-24 | — | — | EP | disclosed |
| EP-2167090-A2 | HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER | University of Maryland, Baltimore (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090048156-A1 | HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER | UNIVERSITY OF MARYLAND, BALTIMORE | 2009-02-19 | — | — | US | disclosed |
| WO-2008154402-A2 | HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108522-A1 | HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER | HDAC5, HDAC1, HDAC4 | LMNA 2987/4885HSD17B10 299/4885CYP2C19 3396/4885 |
| US-20090048156-A1 | HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER | HDAC5, HDAC1, HDAC4 | LMNA 2987/4885HSD17B10 299/4885CYP2C19 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.